Zydus Lifesciences Limited ("the Company") has filed a regulatory update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026. This filing serves as an update to the company's earlier intimation dated October 1, 2026.
The disclosure confirms that the transaction to subscribe to 50% of the total paid-up equity share capital of Zydus Sunshine Lifesciences (Private) Limited ("Zydus Sunshine") has been completed. This investment was made pursuant to a Share Subscription and Shareholders' Agreement ("SSSHA") executed with Sunshine Healthcare Lanka Limited ("Sunshine") and Zydus Sunshine, as previously intimated on June 26, 2026.
Key Transaction Details
- Nature of Transaction: Subscription of equity shares ("Subscription Shares") constituting 50% of the total paid-up capital of Zydus Sunshine.
- Resulting Ownership: Post-subscription, Zydus Sunshine becomes a 50:50 joint venture between Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited.
- Original Timeline: The transaction was initially expected to be completed within 90 working days from the June 26, 2026 intimation.
- Revised Timeline: On October 1, 2026, the Company and Zydus Sunshine mutually agreed to extend the closing date, with an expectation to complete by December 2026.
- Completion Date: The transaction was formally completed on November 11, 2026.
- Reason for Delayed Intimation: The company cited office holidays during the festive season as the reason for the delay in sending this intimation.
The company has requested the exchanges to take this information on record.
The letter is digitally signed by Dhaval Narendra Soni, Company Secretary and Compliance Officer (Membership No. FCS7063) of Zydus Lifesciences Limited.